The company said revenue increased to $35 million for the quarter compared to $21.2 million for the same period of the 2020 fiscal year.

Quarterly highlights cited by the company included its support for the Engineering Biology Research Consortium and its statement of ethics in Engineering Biology Research. Twist also noted its acquisition of iGenomX and launch of the Twist Library Preparation Enzymatic Fragmentation Kit 2.0.

Twist said it aims to increase revenue guidance, which is now expected to be in the range of $129 million to $132 million.

Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Twist acquires iGenomX for $35M
Twist Bioscience has acquired next-generation sequencing library preparation developer iGenomX for $35 million. The deal gives Twist a leg up in...

Twist, Regeneron partner on genetics NGS panel
Twist Bioscience is collaborating with Regeneron subsidiary Regeneron Genetics Center to launch a custom next-generation sequencing (NGS) population genetics...

Twist launches enzymatic fragmentation library prep kit
Twist Bioscience has unveiled its Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to maximize accuracy and...

Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery...